Tumor defense systems using O-glycans

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 10, 2012, Pages 1633-1636

  Tsuboi, Shigeru ^a,b  

^a Oyokyo Kidney Research Institute   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Natural killer cell immunity; O glycan; Tumor metastasis

Indexed keywords

CARBOHYDRATE; GALECTIN 3; GLYCAN; GLYCOPROTEIN; LIGAND; MUCIN 1; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; O GLYCAN; SERINE; THREONINE; TRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

CELL INTERACTION; CELL SURFACE; CELL SURVIVAL; CIRCULATION; DISEASE ACTIVITY; DOWN REGULATION; ENZYME REGULATION; HUMAN; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; METASTASIS INHIBITION; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REVIEW; SURVIVAL TIME; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR REJECTION;

KILLER CELLS, NATURAL; MUCIN-1; NEOPLASMS; POLYSACCHARIDES;

EID: 84867257010     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00367     Document Type: Review

References (22)

1. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell, 147, 275-292 (2011).
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat. Immunol., 9, 503-510 (2008).
3. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J. Biomed. Biotechnol., 2011, 676198 (2011).
4. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science, 291, 2364-2369 (2001).
5. Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Katsuyama T, Fukuda M. Carcinoma-associated expression of core2 beta-1,6-N- acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res., 57, 5201-5206 (1997).
6. Machida E, Nakayama J, Amano J, Fukuda M. Clinicopathological significance of core 2 beta-1,6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization. Cancer Res., 61, 2226-2231 (2001).
7. Hagisawa S, Ohyama C, Takahashi T, Endoh M, Moriya T, Nakayama J, Arai Y, Fukuda M. Expression of core2 beta-1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology, 15, 1016-1024 (2005).
8. Hatakeyama S, Kyan A, Yamamoto H, Okamoto A, Sugiyama N, Suzuki Y, Yoneyama T, Hashimoto Y, Koie T, Yamada S, Saito H, Arai Y, Fukuda M, Ohyama C. Core 2 N-acetylglucosaminyltransferase- 1 expression induces aggressive potential of testicular germ cell tumor. Int. J. Cancer, 127, 1052-1059 (2010).
9. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J., 30, 3173-3185 (2011).
10. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol., 9, 495-502 (2008).
11. Rabinovich GA, Rubinstein N, Fainboim L. Unlocking the secrets of galectins: a challenge at the frontier of glyco-immunology. J. Leukoc. Biol., 71, 741-752 (2002).
12. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev. Mol. Med., 10, e17 (2008).
13. Saegusa J, Hsu DK, Chen HY, Yu L, Fermin A, Fung MA, Liu FT. Galectin-3 is critical for the development of the allergic inflammatory response in a mouse model of atopic dermatitis. Am. J. Pathol., 174, 922-931 (2009).
14. Tsuboi S, Hatakeyama S, Ohyama C, Fukuda M. Two opposing roles of O-glycans in tumor metastasis. Trends Mol. Med., 18, 224-232 (2012).
15. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 419, 734-738 (2002).
16. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol., 171, 6891-6899 (2003).
17. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol., 180, 7249-7258 (2008).
18. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol., 6, 928-937 (2005).
19. Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA, Zwirner NW. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol., 180, 4606-4614 (2008).
20. Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Habuchi T, Arai Y, Fukuda M, Ohyama C, Tsuboi S. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int. J. Oncol., 40, 1831-1838 (2012).
21. Radhakrishnan P, Chachadi V, Lin MF, Singh R, Kannagi R, Cheng PW. TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem. Biophys. Res. Commun., 409, 436-441 (2011).
22. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin. Dev. Immunol., 2011, 565187 (2011).